Olivier Bylicki
Overview
Explore the profile of Olivier Bylicki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Vergnenegre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, et al.
Lung Cancer
. 2023 Mar;
178:191-197.
PMID: 36868180
Objective: To evaluate the safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage IV non-small-cell lung cancer. Methods: This was a multicenter, open-label, single-arm Phase II study performed...
12.
Bylicki O, Tomasini P, Radj G, Guisier F, Monnet I, Ricordel C, et al.
Eur J Cancer
. 2023 Feb;
183:38-48.
PMID: 36801605
Background: Previous reports showed limited efficacy of immune checkpoint inhibitors as single-agent treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation or ALK/ROS1 fusion. We...
13.
Boussageon M, Swalduz A, Chouaid C, Bylicki O
BioDrugs
. 2022 Nov;
37(1):121.
PMID: 36401075
No abstract available.
14.
Justeau G, Huchot E, Simonneau Y, Roa M, Le Treut J, Le Garff G, et al.
Lung Cancer
. 2022 Nov;
174:45-49.
PMID: 36323057
Objectives: Few data are available on the impact of KRAS mutation in patients with advanced non-squamous non-small cell lung cancer (aNSCLC) treated with immunotherapy. This analysis assessed the impact of...
15.
Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N, et al.
Lancet Reg Health Eur
. 2022 Sep;
22:100492.
PMID: 36108315
Background: Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report results from the French KBP-2020 real-life cohort. Methods: KBP-2020 was a prospective cohort that included all...
16.
Riviere F, Cazes A, Bylicki O, Le Floch H, Gaspard W, Cornetto M, et al.
Indian J Thorac Cardiovasc Surg
. 2022 Feb;
38(2):142-148.
PMID: 35221552
Objectives: The diagnosis of interstitial lung disease is based on clinical and biological analysis associated with computed tomography (CT) pattern after discussion in multidisciplinary discussion. Lung transbronchial cryobiopsy has emerged...
17.
Gendarme S, Bylicki O, Chouaid C, Guisier F
Curr Oncol
. 2022 Feb;
29(2):641-658.
PMID: 35200557
The gene plays a major role in the oncogenesis of numerous tumors. rearrangement is found in 0.9-2.6% of non-small-cell lung cancers (NSCLCs), mostly lung adenocarcinomas, with a significantly higher rate...
18.
Boussageon M, Swalduz A, Chouaid C, Bylicki O
BioDrugs
. 2022 Feb;
36(2):137-151.
PMID: 35147894
Treatment of metastatic non-small-cell lung cancers (NSCLCs) has long been based on cytotoxic chemotherapy. Immune checkpoint inhibitors (ICIs), notably monoclonal antibodies directed against programmed cell death protein-1 (PD-1) or its...
19.
Martel-Lafay I, Monnet I, Lardy-Cleaud A, Danhier S, Salem N, Gallocher O, et al.
Curr Oncol
. 2021 Oct;
28(5):3804-3811.
PMID: 34677242
Concomitant radiochemotherapy (RTCT) is the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). However, in patients with a peripheral primary tumor, the irradiated volume may include a...
20.
Bylicki O, Delarbre D, Mayet A, Ferrier A, Perisse A, Malle C, et al.
Int J Infect Dis
. 2021 Sep;
112:8-12.
PMID: 34508860
Objective: A better understanding of the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is critical to predict its dynamics within the general population and its impact on...